NCT02428400 - Safety and Tolerability of TG1050: A Dose-finding Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions

Chronic Hepatitis B

Interventions

BIOLOGICAL

TG1050

TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer

BIOLOGICAL

Placebo

Placebo: adenovirus reference material (ARM) buffer

Trial Locations (12)

Edmonton

Calgary

Montreal

Grenoble

Lyon

Nancy

Paris

Strasbourg

Freiburg im Breisgau

Hamburg

Hanover

Mainz